Foghorn Therapeutics’ Senior Director Dave Lahr highlights advances in epigenomic methods—CUT&RUN, ATAC-seq, and bisulfite sequencing—that enable high-resolution chromatin profiling to elucidate drug mechanisms of action (MOA). These assays provide precise insights into changes induced by targeted protein degraders and enzyme inhibitors, facilitating accelerated drug development and improved prediction of patient responses. This emerging toolkit is essential for dissecting complex transcriptional dynamics associated with epigenetic therapies.